The Mother of All Clinical Trials, Part I

Part I: An Incipient Revolution in Epidemiology

There are a great number of promising interventions that might have anti-aging benefits, singly and in combination.  There is a testing bottleneck, which means that we don’t know what works. By way of contrast, there is a well-documented catalog of life extension interventions in lab worms, but for humans we’re mostly in the dark.  To complicate things further, lab worms are clonal populations, while every human is different, and there are growing indications that many if not most medications work for some people and not others.

Horvath’s methylation clock is a disruptive technology that could make human testing of longevity interventions ten times faster and 100 times cheaper than it has been in the past.  No one is yet doing this kind of testing, but you and I should be advocating vigorously, and volunteering as subjects to help test whatever it is that we are already doing.

---

Let me begin with the punchline, and work backward to build a foundation under the idea.  I think we might learn a great deal and push the science of anti-aging medicine forward with a study encompassing about 10,000 people like you and me—people who are aware of the long-term consequences of their diet, exercise, supplements, and medications—10,000 people who are trying different combinations of things in a conscious effort to maintain long-term health and extend their lives.  We need a standard form for recording our individual habits and a standard measure of progress. Subjects will be required to

• keep diaries of what they are doing for long-term health  (It would be helpful but not necessary that they keep to the same program for a year or two.)
• send in blood or urine samples at the beginning and end of a year for methylation testing
• sign up for a database so all their records can compiled

Given a database like this, multivariate statistical techniques can, in principle, separate the effects of different interventions individually, and also their interactions.

The idea is only as good as the Horvath clock.  Can we detect differences in aging rate over a time period as short as a year or two?  And how sure are we that the Horvath clock really captures the differences that affect aging and long-term health?  That’s what next week’s article will be about.

The present cost of methylation testing is several hundred dollars, but a funder would only have to put up a fraction of that. The rest would be covered by participants themselves, and Zymo Research, the only company offering commercial testing of methylation age, would offer bulk discounts because they are investing in their future, and because their costs are likely to drop with volume.

So far, I’ve talked about this with Steve Horvath of UCLA, Brian Delaney of LEF, Larry Jia of Zymo, and Elissa Epel of UCSF.  All are enthusiastic about the idea. Though none is yet convinced to throw resources into the project, I believe that this trial or something much like it will begin within a year, as scientists and funders have a chance to recognize its potential and rearrange their plans appropriately.  (I will also approach Aubrey de Grey at SENS, but their primary commitment is to a different model, developing new interventions rather than testing what we have already.)

 

Background

For several years I’ve been talking to anyone who will listen about the importance of testing.  (Here’s a 2015  link, and here’s an update from two months ago.)  Aging clocks based on DNA methylation are a disruptive technology which will change the way we screen putative longevity treatments.  We now have the potential to learn in a very few years what works and what does not.

There are a great number of promising interventions that might have anti-aging benefits, singly and in combination.  Some are already approved and safe for use in humans, yet we don’t know what will be most effective. Because human longevity studies are prohibitively slow and expensive, none have ever been funded or conducted.  (We know only accidentally that aspirin and metformin lower mortality rates in humans, because these drugs were prescribed to tens of millions of people beginning in the 1960s for cardiovascular disease and diabetes, respectively, with no premonition that they might extend lifespan.)

We have relied on animal tests, biochemical theory, and guesswork because testing in humans has been impractical.  Epidemiological studies require treating a very large population and following them over a course of decades. Even very substantial difference is mortality rates can be difficult to detect because the baseline mortality rate is low, because researchers inevitably lose track of some subjects over such long time scales, and because there are so many confounding variables that must be overcome with sheer numbers.

Testing of anti-aging interventions in humans has been so expensive and slow that we have been forced to make inferences from animal tests, supplemented by historic (human) data from drugs that happen to have a large user base going back decades.  As it turns out, it is much easier to extend lifespan in worms than in mammals, and even the interventions that work in rodents don’t always work in humans. Conversely, there are drugs that work in humans that don’t work in mice—how are we to find them?

We know so much more about life extension in C. elegans worms than in people because worms live only a few weeks, are easily cloned, and can be grown by the thousands in standard laboratory conditions.  Humans are not so easily controlled, they can’t be genetically engineered or cloned, and their lives can’t be manipulated in the interest of science.  It takes decades to document the long-term effects of dietary changes, drugs, supplements and exercise routines, and it generally requires thousands of people to separate the effects of one particular intervention from all the differences in genetics and lifestyle that distinguish human individuals.

Just this year, a test is available that is accurate enough to measure anti-aging benefits on short time scales, without waiting for subjects to die.  DNAm PhenoAge is a simple blood test developed at the UCLA lab of Steve Horvath.  It determines risk of age-related mortality accurate to about 1 year of biological age.  Averaging over just a hundred people pinpoints biological age with accuracy of one month.  This implies that an anti-aging benefit can be detected with high reliability using a test population of just a few hundred people, followed for two years, tested at the beginning and end of this period.  A study that might have required fifteen years and cost hundreds of millions of dollars can now be completed in two years at a cost of less than $1 million. When this new technology is embraced, we will have the means to separate the most effective treatment combinations from a large field of contenders.

1. Testing is Important

We have a program in basic science that will eventually lead to understanding of aging at a molecular level.  This will suggest molecular interventions that can alter the course of aging. This approach is a sure bet, and it will yield a great deal of interesting science and clinical applications along the way.  The drawback is that it is slow.  At least several decades will be required to understand aging from the system level down to the molecular level.  What can be done to accelerate progress toward substantial anti-aging remedies?

You might think that the bottleneck is in ideas.  What we need is a disruptive idea. Something like CRISPR or the Yamanaka factors, or maybe some engineered molecule that leaves rapamycin in the dust.

I don’t think so.  How would we recognize this great idea if we saw it?  If it were rather conventional, it’s unlikely it would produce revolutionary results.  On the other hand, if the idea were profoundly different and innovative, why would we believe in it without extensive testing?  And who would pay for the testing?

I believe that testing is really the bottleneck here.  We may well have our powerful anti-aging tonic already in hand, and we don’t know it.  And if the breakthrough is yet to come, we will need a way to recognize that it works.

Two years ago, I proposed that the best promise is in combinations of known therapies.

We know what they do individually, but we don’t know how they interact among themselves.  In reality, of course, we’ll never see that 172% life extension.  Almost all interactions are expected to be redundancy—in other words A and B together are a marginal improvement over either A or B separately.  But occasionally, we will discover that A and B synergize. A and B administered together yield life extension greater than the sum of what is available from each of them separately.

But there are an enormous number of combinations to test.  How are we going to find those combinations that synergize together?

2. Testing in humans is slow and expensive

It’s not just because humans require a level of care and safety that you don’t worry about in animal tests.  It’s the length of the human lifespan.

If you’re studying an old drug like metformin or aspirin, then you have a database of people who have used it for decades, and you can look for small differences in their rates of disease or mortality.

But suppose you want to try a new remedy, or a new combination of remedies?  Typically, you would choose several thousand people as a test group. You need to wait for a substantial number of them to die, so you want to start as late as possible.  On the other hand, it’s easier to maintain the health of a younger person than to restore the health of an older person, so you want subjects as young as possible. So perhaps you compromise with an age around 50 or 60.

Then you administer the drug or combination of drugs in half the subjects and a placebo in the other half.  You follow them for a decade and monitor compliance. How many of them are still taking your placebo 10 years later?  Out of a sample of 1,000 sixty-year-olds, you expect 120 of them to die before their 70th birthday. Now suppose you had an intervention that would cut the death rate by 10%, so only 108 of them died.  The trouble is that statistically, you can’t tell the difference between 108 and 120.  The random fluctuations will overwhelm this difference.

How large a sample would you have to start with in order to detect that difference with 95% confidence? For N=6,000 tests + 6,000 controls, you would detect a 10% difference with 95% confidence half the time.  If you wanted to be 90% sure that your results would be statistically significant, you would need 15,000 test subjects and 15,000 controls, tracked for 10 years.  The cost would be in the hundreds of millions  of dollars.

Another way to think about the same example:  Imagine that the treatment you are testing does not immediately lower the mortality rate, but it slows the rate of aging by 20%.  The result is about the same—a 10% lower mortality over 10 years.

In New York’s Einstein School of Medicine, Nir Barzilai is organizing the first ever clinical trial of an anti-aging drug.  Metformin is the drug he chose, based on lower rates of all-cause mortality, cancer, and Alzheimer’s disease among people who have been prescribed metformin to control diabetes.  The risk of Alzheimer’s between age 60 and 80 is about 10%. Data from people taking metformin suggest this could reduce this to 7% [Knowler, 2002].  Barzilai is still trying to fund this study with about $50 million.  For that, the TAME study hopes to recruit 3,000 subjects (1500+1500) [Sciencemag 2015].  What is the probability that they will have results significant at the (p<0.05) level?  Answer: 83%. You may think that’s pretty good. Or you may be horrified that he could spend $50 million and there’s a 1 in 7 chance that, just because of dumb luck, the trial wouldn’t produce significant results.  There’s a footnote in the 83% number: The 31% Alzheimer’s risk reduction comes from a study of younger people, but Barzilai is planning to recruit subjects from 65 to 79 years old because the rate of AD is higher.

3. Suppose we could accurately measure effects on aging without having to wait…

What’s the alternative?  I’m so glad you asked. Suppose we could actually measure aging.  We don’t have to wait for someone to die or be diagnosed with dementia.  We can do a blood test instead and determine that “this subject has aged 1.5 years”  or “this subject has been rejuvenated by 0.5 years”.

To reimagine the TAME protocol with an aging clock, we need to add an assumption about what the effect of metformin might be on the Horvath clock (or successor).  From reduction in mortality combined with an actuarial table, we might infer an age setback. Lamanna 2010 reports a OR=0.80.  Facila 2017 report OR=1.34/2.24=0.60.   Bannister 2014 reports OR=0.85 when comparing diabetics on metformin with non-diabetics (yes — metformin in some studies reduces mortality for diabetics lower than it would have been if they didn’t have diabetes in the first place).  The logarithmic increase in mortality for a 60-year-old is about 0.075, corresponding to a range for actuarial setback of 2 to 7 years for long-term metformin use.

Let’s say the experiment lasts 2 years and after 2 years on metformin, the subjects might have aged only 1¾  years. Very conservative, I think. Compared to 3000 subjects over 10 years, You could get equivalent results from a Horvath clock over 2 years time with 200 subjects.  The total cost of the study could be reduced from $50 million to less than $1 million.

These probablities are not difficult to compute, but their inputs are very uncertain.  We don’t know how much scatter there will be in the difference between two Horvath clock readings when repeated for the same person.  I’ve assumed 1.414 years. It coud well be better. We don’t know whether metformin will slow the epigenetic clock, and by how much. It may be that we will get that same 3-months benefit in one year instead of two.

---

The Bottom Line

Numbers are my thing, and I’m sorry if I’ve left your head spinning.  The take-home is that by switching from traditional epidemiological studies of mortality to the Horvath clock, we can get the same information five times faster and 100 times cheaper. 

For example: Barzilai’s TAME study is projected to cost $50 million, it will take 10 years, and it will teach us the benefits of just one drug. The study I’m proposing will cost less than $10 million and most of this will be covered by Zymo (as discounts) and by subjects themselves. It will take only 2 years, and we will learn about a dozen different interventions and their interactions.

---

Next week, Part II: Reasons to think that the Horvath Clock will be up to this task